Torigen Pharmaceuticals is a technology company.
Torigen Pharmaceuticals has raised $16.0M across 2 funding rounds.
Torigen Pharmaceuticals has raised $16.0M in total across 2 funding rounds.
Torigen Pharmaceuticals has raised $16.0M in total across 2 funding rounds.
Torigen Pharmaceuticals's investors include Emerald Development Managers, BBG Ventures, Female Founders Fund, Hans Tung, Robin Li, SoGal Ventures.
Torigen Pharmaceuticals is a veterinary biotechnology company developing personalized cancer immunotherapies for companion animals like dogs, cats, and horses. Its lead product, VetiVax, is an autologous cancer vaccine created from a patient's own surgically resected tumor tissue, combined with MIM™ (matrix immune modulator) to stimulate the immune system, reduce tumor size, and inhibit metastasis.[1][2][3] The company serves veterinary clinics by providing expert pathology diagnostics and prescription therapies, addressing the high cancer incidence in pets—over 4 million dogs and cats diagnosed annually in the US, with over 50% of dogs over age 10 dying from it.[1][4] Torigen has treated thousands of animals, works with about 500 US clinics, and is building a pipeline of new therapies while launching clinical studies.[1][3][5]
Torigen emerged from cancer research initially aimed at humans but pivoted to the veterinary market for faster impact, lower development costs, and unmet needs in companion animal cancer care.[5] The founding team includes cancer researchers, veterinarians, and animal health professionals passionate about extending pet lives, driven by the recognition that pets are family members.[1][6] A pivotal decision was commercializing tumors as the antigenic backbone for autologous vaccines, leveraging existing patents, publications, and data; they shifted from a human focus to veterinary, starting with dogs, cats, and horses.[5] Early traction came from safety trials, peer-reviewed efficacy data, and nationwide availability through 500 clinics, with ongoing pivots like in-house manufacturing for quality control and re-exploring kit-based models internationally.[2][5]
Torigen rides the personalized immunotherapy wave in veterinary medicine, mirroring human oncology advances like tumor vaccines but adapted for faster, cost-effective animal health deployment.[3][5] Timing aligns with rising pet humanization—owners spend more on advanced care amid 6 million annual US dog cancer diagnoses—and veterinary overload from busy practices.[1][5] Market forces favoring it include regulatory ease under USDA for vet biologics, peer-reviewed data showing tumor reduction/metastasis inhibition, and a gap in non-toxic alternatives to chemo.[2] It influences the ecosystem by partnering with 500+ clinics, fueling cancer research via retained tumors, and bridging vet-human translation, potentially accelerating biotech pipelines.[3][5]
Torigen is poised for expansion with clinical studies on existing and pipeline products, international kit pivots, and capital raises to scale adoption and de-risk assets.[1][5] Trends like AI-enhanced pathology, vet-human crossovers, and premium pet health spending will shape growth, potentially capturing more of the underserved market beyond chemo.[5] Its influence may evolve from niche innovator to pipeline leader, humanizing biotech by proving personalized vaccines in vets first—echoing its core mission to improve pet lives through immune-powered therapies.[1][6]
Torigen Pharmaceuticals has raised $16.0M across 2 funding rounds. Most recently, it raised $13.0M Series A in May 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2022 | $13.0M Series A | Emerald Development Managers | |
| Feb 1, 2019 | $3.0M Series A | BBG Ventures, Female Founders Fund, Hans Tung, Robin Li, SoGal Ventures |